依普利酮获批适应症

Approved indications: In 2002, eplerenone (INSPRA) was approved in the United States for the treatment of essential hypertension and heart failure after myocardial infarction.

Acute myocardial infarction (AMI) is myocardial necrosis caused by acute and persistent ischemia and hypoxia of the coronary arteries. Clinical symptoms mostly manifest as severe and long-lasting retrosternal pain or aggravation of original angina pectoris. It can also be complicated by arrhythmia, shock or heart failure, which is often life-threatening. China has shown an obvious upward trend in recent years, with at least 500,000 new cases every year and at least 2 million current patients.

Hypertension is the most common chronic disease and the main risk factor for cardiovascular and cerebrovascular diseases. Hypertension refers to an increase in systemic arterial blood pressure (systolic blood pressure and/or diastolic blood pressure) as the main feature (systolic blood pressure ≥ 140 mm Hg mm Hg, diastolic blood pressure ≥ 90 mm Hg mm Hg). Clinically, it may be accompanied by functional or organic damage to the heart, brain, kidney and other organs. About 60% of patients with hypertension have a family history. It is currently believed to be caused by polygenic inheritance, and 30% to 50% of patients with hypertension have a genetic background.

(INSPRA) related clinical trials have shown that eplerenone (INSPRA) has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Eplerenone (INSPRA) has a protective effect on the liver, heart disease, and kidneys without damaging the organs. Eplerenone (INSPRA) can promote urination without losing potassium. It also has a good antihypertensive effect on simple systolic hypertension and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, eplerenone (INSPRA) can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.